Iovance Biotherapeutics Files 8-K on Financial Condition
Ticker: IOVA · Form: 8-K · Filed: Feb 28, 2024 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Feb 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, 8-K
TL;DR
**Iovance Biotherapeutics just dropped an 8-K on their financial and operational status, keeping the market in the loop.**
AI Summary
IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on February 28, 2024, regarding its financial condition and results of operations. The filing indicates the company's current status and adherence to SEC regulations, with its business address at 825 Industrial Road, 4th Floor, San Carlos, CA 94070. This report provides an update on the company's financial standing without disclosing specific monetary figures in the provided text.
Why It Matters
This filing provides an update on Iovance Biotherapeutics' financial and operational status, offering transparency to investors and the market regarding its ongoing business health.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate adverse events.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- February 28, 2024 (date) — Date of Report
- Delaware (location) — State of Incorporation
- 001-36860 (other) — Commission File Number
- 75-3254381 (other) — I.R.S. Employer Identification No.
- 825 Industrial Road, 4th Floor, San Carlos, CA 94070 (location) — Business Address
FAQ
What is the purpose of this 8-K filing by IOVANCE BIOTHERAPEUTICS, INC.?
The 8-K filing by IOVANCE BIOTHERAPEUTICS, INC. is to report on the company's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits, as of February 28, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 28, 2024.
What is the state of incorporation for IOVANCE BIOTHERAPEUTICS, INC.?
IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.
What is the business address of IOVANCE BIOTHERAPEUTICS, INC. as stated in the filing?
The business address of IOVANCE BIOTHERAPEUTICS, INC. is 825 Industrial Road, 4th Floor, San Carlos, CA 94070.
What is the Commission File Number for IOVANCE BIOTHERAPEUTICS, INC.?
The Commission File Number for IOVANCE BIOTHERAPEUTICS, INC. is 001-36860.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 9.4 · Accepted 2024-02-28 16:05:21
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per share IOVA The Nasdaq Stock Marke
Filing Documents
- tm247491d1_8k.htm (8-K) — 26KB
- tm247491d1_ex99-1.htm (EX-99.1) — 76KB
- 0001104659-24-028704.txt ( ) — 283KB
- iova-20240228.xsd (EX-101.SCH) — 3KB
- iova-20240228_lab.xml (EX-101.LAB) — 33KB
- iova-20240228_pre.xml (EX-101.PRE) — 22KB
- tm247491d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 28, 2024, Iovance Biotherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Iovance Biotherapeutics, Inc., dated February 28, 2024. 104 Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iovance Biotherapeutics, Inc. Dated: February 28, 2024 By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D. Title: Interim CEO and General Counsel